Brief: Caliway Announced EMA Orphan Drug Designation Granted To CBL-514 For Dercum's Disease Treatment
12/11/2024 13:33
Nov 12 (Reuters) - Caliway Biopharmaceuticals Co Ltd
6919.TW :
* CALIWAY ANNOUNCED EMA ORPHAN DRUG DESIGNATION GRANTED TO
CBL-514
FOR DERCUM'S DISEASE TREATMENT
Source text: ID:nPncbMKSpa
Further company coverage: 6919.TW
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CALIWAY BIOPHARMACEUTICALS
See all newsBrief: Caliway: New Drug CBL-514 Phase II Clinical Results' Demonstrated Efficacy
Brief: Caliway Says A Phase 2B Study For Reducing Abdominal Subcutaneous Fat Met All Main Goals
Brief: Caliway Announced EMA Orphan Drug Designation Granted To CBL-514 For Dercum's Disease Treatment
Brief: Caliway Biopharmaceuticals Expects IND Approvals For Cbl-514